Reason for the change This change was for clarification purposes . Syne qua non study no: TAX12001 Targovax study no: CT TG01 -01 Page 1 of 4 Date: 25OCT2018 Version: Addendum 2.0 Final 1.0 ST/form/038/1 A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas Targovax ASA Study No: CT TG01 -01 Syne qua non Ltd Study No: TAX12001 Statistical Analysis Plan Addendum Version: Addendum 2.0 Final 1.0 Date: 25 October 2018 For Syne qua non Ltd – Lead Statistician For Targovax ASA If signing manually, please include: Signature + Date + Full Name + Position Syne qua non study no: TAX12001 Targovax study no: CT TG01 -01 Page 2 of 4 Date: 25OCT2018 Version: Addendum 2.0 Final 1.0 ST/form/038/1 Contents 1 INTRODUCTION ............................................................................................................................. 4 2 CHANGES TO the FINAL SAP ....................................................................................................... 4 2.1 Immune Response ...................................................................................................................... 4 Syne qua non study no: TAX12001 Targovax study no: CT TG01 -01 Page 3 of 4 Date: 25OCT2018 Version: Addendum 2.0 Final 1.0 ST/form/038/1 LIST OF ABBREVIATIONS DTH Delayed Type Hypersensitivity IAS Immune Analysis Set MIAS Modified Immune Analysis Set Syne qua non study no: TAX12001 Targovax study no: CT TG01 -01 Page 4 of 4 Date: 25OCT2018 Version: Addendum 2.0 Final 1.0 ST/form/038/1 1 INTRODUCTION This is an addendum to the final statistical analysis plan (SAP) dated 02 MAY 2018 documenting additional analyses following database lock. Full details of the changes are detailed below.